Loading...

News List

首个抗癌制剂PAC-1在人类癌症临床试验中展现出巨大希望

2023-01-09


首个抗癌制剂PAC-1在人类癌症临床试验中展现出巨大希望

来自伊利诺伊大学香槟分校等机构的科学家们通过研究发现,在临床试验中,PAC-1能有效阻断5名神经内分泌癌症患者机体肿瘤的生长,并能减少其中两名患者机体的肿瘤尺寸,同时还展现出了抵御肉瘤的一些治疗活性。PAC-1是一种能刺激癌细胞发生程序性细胞死亡的药物,其在I期临床试验中发现仅会对晚期癌症患者产生轻微的副作用。

Pre: adagrasib (MRTX849), an oral KRAS G12C inhibitor developed by Mirati Therapeutics, is on the market

Next: PAC-1, the first anti-cancer agent, has shown great promise in human cancer clinical trials

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.